Heart rate variability in patients with overactive bladder or stress urinary incontinence.
Completed
- Conditions
- overactive bladderurgency10004994
- Registration Number
- NL-OMON36299
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Female sex
Age 18 - 75 years
Diagnosis of idiopathic overactive bladder or stress incontinence
Exclusion Criteria
Antimuscarinic medication
Neurologic disease
cardiac disease
Medication influencing heart rate
Pregnancy
Urinary tract infection
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Difference in LF/HF ratio between patients with IOAB and SUI<br /><br>Difference in LF/HF between full and empty bladder in patients in both groups </p><br>
- Secondary Outcome Measures
Name Time Method <p>Difference in total power (TP), SDNN, RMSSD, VLF, HF and LF between patients<br /><br>with IOAB and SUI<br /><br>Difference in total power (TP), SDNN, RMSSD, VLF, HF and LF between full and<br /><br>empty bladder in patients in both groups </p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link autonomic nervous system dysfunction to overactive bladder and stress urinary incontinence in NL-OMON36299?
How does heart rate variability (HRV) monitoring compare to urodynamic studies in predicting treatment outcomes for OAB/SUI patients?
Which HRV-derived biomarkers (e.g., LF/HF ratio, SDNN) correlate with symptom severity in overactive bladder or stress urinary incontinence?
Are there adverse cardiovascular events associated with autonomic dysregulation in patients with neurogenic bladder dysfunction?
What combination therapies (e.g., anticholinergics, pelvic floor exercises) synergize with HRV-based interventions for OAB/SUI management?